Annovis Bio, Inc.
Biotechnology ResearchPennsylvania, United States11-50 Employees
Annovis Bio, Inc. is a Phase 3 clinical-stage biotechnology company based in Malvern, Pennsylvania, focused on neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Its lead oral therapy, buntanetap, targets the production of multiple neurotoxic proteins by acting at the RNA translation step, with the goal of addressing upstream drivers of neurodegeneration. The company also explores applications in other conditions tied to toxic protein accumulation, including traumatic brain injury and stroke, within a broader neurodegenerative portfolio. Clinical data from 13 studies involving more than 1,200 participants indicate buntanetap has a favorable safety profile and potential cognitive benefits, including improvements in early-stage AD and early PD with amyloid pathology. Annovis is actively enrolling patients in a pivotal Phase 3 trial in early Alzheimer's disease in the United States and pursuing additional programs to transform treatment for neurodegenerative disorders. In 2026, the company pursued external partnerships to support its development, such as a collaboration with NeuroRPM to integrate an AI-driven movement data platform into a Parkinson's study, reflecting its move toward incorporating digital health tools in clinical research.
1-888-653-2347 
support@leadiq.com 
